Company Overview and News

4
The Singapore stocks to watch amid Trump and Kim's historic meet

2018-06-11 theedgemarkets
SINGAPORE (June 11): There’s more than one way to play the Trump-Kim summit in the world of stocks.
S07 G13 0069 SHALF GIGNF O39 GIGNY SHALY

4
The Singapore Stocks to Watch While Trump Meets Kim - Bloomberg

2018-06-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
S07 G13 0069 SHALF GIGNF O39 GIGNY SHALY

10
The Singapore stocks to watch during the Trump-Kim summit

2018-06-10 scmp
There’s more than one way to play the Trump-Kim summit in the world of stocks. Apart from the obvious North Asian and US equities, there’s another geography investors can consider: Singapore – and its consumer stocks, to be precise.
S07 C6L SK7 CDGLF BTKGF 5DA ACTRF SHALF SINGY Q5T O39 GIGNY 42R A68U G13 0069 CDGLY H15 A34 GIGNF FHOSY J85 SHALY SINGF

0
KSK Group Joanne Kua in Forbes Asia's inaugural Emergent 25 list

2018-05-03 thestar.com.my
SINGAPORE: Joanne Kua, Group Chief Executive Officer and Executive Director of Malaysia-based KSK Group, is listed in the Forbes Asia's inaugural Emergent 25 List which honours businesswomen making their mark in regional enterprises. Kua, 33, who is also the managing director of KSK Land Sdn Bhd, joined her father's insurance and finance business seven years ago. Since then, she has transformed KSK Group into a diversified conglomerate by adding property development and technology investments to its portfolio and the group's total assets was now worth around US$410 million (US$1 = RM3.
S07 0069 SHALF SHALY

3
Director share buying surges to US$37.2m, despite shorter trading week

2018-04-01 scmp
Director share buying surged for the second straight week, while selling rose for the fourth straight week, based on filings on the exchange during the holiday-shortened week of March 26 to 29.
S07 0069 2007 0700 SHALF SHALY

Related Articles

REPH: Recro Pharma Analysis and Research Report

3h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

3h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

4h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...